Filing Flows › Niagen Bioscience (NAGE) › Q3 2026 › vs Q2 2026
Niagen Bioscience (NAGE) Q3 2026 vs Q2 2026 (quarter over quarter)
Niagen Bioscience's revenue fell $2.6M (-9%) from $29.8M in Q2 2026 to $27.2M in Q3 2026. The biggest changes: Ingredients segment −$1.6M (-29%); Consumer Products segment −$842K (-3%).
Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Consumer Products segment | $23.3M | $24.2M | −$842K | -3% |
| Ingredients segment | $3.8M | $5.4M | −$1.6M | -29% |
| Revenue | $27.2M | $29.8M | −$2.6M | -9% |
| Other income, net | $414K | $369K | $45K | +12% |
| Net loss | $1.2M | −$963K | $2.1M | — |
| Costs & expenses | $28.8M | $30.2M | −$1.4M | -5% |
| Operating costs | $28.8M | $29.1M | −$306K | -1% |
| Cost of revenue | $10.1M | $10.5M | −$384K | -4% |
| Research & development | $1.8M | $1.5M | $283K | +19% |
| Sales & marketing | $8.7M | $10.1M | −$1.4M | -14% |
| General & admin | $8.2M | $7.0M | $1.2M | +17% |
| Operating cash sources | $3.8M | $1.8M | $2.0M | +110% |
| Depreciation & amortization | $290K | $291K | −$1K | -0.3% |
| Share-based compensation | $1.5M | $1.7M | −$201K | -12% |
| Working capital & other | $2.0M | −$205K | $2.2M | — |
| Net loss absorbed | $1.2M | −$963K | $2.1M | — |
| Operating cash flow | $2.6M | $2.8M | −$147K | -5% |
Questions
How much did Niagen Bioscience's revenue grow quarter over quarter in Q3 2026?
Niagen Bioscience's revenue fell $2.6M (-9%) from $29.8M in Q2 2026 to $27.2M in Q3 2026.
What drove Niagen Bioscience's revenue change in Q3 2026?
Ingredients segment −$1.6M (-29%); Consumer Products segment −$842K (-3%).